Reply

Christine E. McLaren, James C. Barton, Pradyumna D. Phatak, Mary J. Emond, V. Nathan Subramaniam, Lyle C. Gurrin, Paul C. Adams, Lawrie W. Powell, Grant A. Ramm, Gregory J. Anderson, Gordon D. McLaren – 29 September 2015

Differing impact of the deletion of hemochromatosis‐associated molecules HFE and transferrin receptor‐2 on the iron phenotype of mice lacking bone morphogenetic protein 6 or hemojuvelin

Chloé Latour, Céline Besson‐Fournier, Delphine Meynard, Laura Silvestri, Ophélie Gourbeyre, Patricia Aguilar‐Martinez, Paul J. Schmidt, Mark D. Fleming, Marie‐Paule Roth, Hélène Coppin – 25 September 2015 – Hereditary hemochromatosis, which is characterized by inappropriately low levels of hepcidin, increased dietary iron uptake, and systemic iron accumulation, has been associated with mutations in the HFE, transferrin receptor‐2 (TfR2), and hemojuvelin (HJV) genes.

Long‐term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study

Vincent Wai‐Sun Wong, Grace Lai‐Hung Wong, Judy Ching‐Lam Yeung, Chloe Yuk‐Kiu Fung, Jasmine Ka‐Lei Chan, Zoe Hoi‐Yi Chang, Chelsia Tsz‐Yan Kwan, Hiu‐Wan Lam, Jenny Limquiaco, Angel Mei‐Ling Chim, Cheuk‐Man Yu, Henry Lik‐Yuen Chan – 25 September 2015 – There is ongoing debate on whether screening for nonalcoholic fatty liver disease (NAFLD) is worthwhile in high‐risk groups. Because of shared risk factors, NAFLD is highly prevalent in patients with coronary artery disease.

Mixed lineage kinase 3 mediates release of C‐X‐C motif ligand 10–bearing chemotactic extracellular vesicles from lipotoxic hepatocytes

Samar H. Ibrahim, Petra Hirsova, Kyoko Tomita, Steven F. Bronk, Nathan W. Werneburg, Stephen A. Harrison, Val S. Goodfellow, Harmeet Malhi, Gregory J. Gores – 25 September 2015 – Mixed lineage kinase 3 (MLK3) deficiency reduces macrophage‐associated inflammation in a murine model of nonalcoholic steatohepatitis (NASH). However, the mechanistic links between MLK3 activation in hepatocytes and macrophage‐driven inflammation in NASH are uncharted.

Interferon lambda 4 genotypes and resistance‐associated variants in patients infected with hepatitis C virus genotypes 1 and 3

Kai‐Henrik Peiffer, Lisa Sommer, Simone Susser, Johannes Vermehren, Eva Herrmann, Matthias Döring, Julia Dietz, Dany Perner, Caterina Berkowski, Stefan Zeuzem, Christoph Sarrazin – 25 September 2015 – Single‐nucleotide polymorphisms (SNPs) in the interferon lambda 4 (IFNL4) gene are predictors for treatment success in patients with hepatitis C virus (HCV) infection. For direct‐acting antiviral combinations only weak association with IFNL4 SNPs was observed. Little is known about potential selections of resistance‐associated variants (RAVs) by the IFNL4 genotype.

Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats

Guillermo Fernández‐Varo, Denise Oró, Edward Earl Cable, Vedrana Reichenbach, Silvia Carvajal, Bernardino González de la Presa, Kazimierz Wiśniewski, Pere Ginés, Geoffrey Harris, Wladimiro Jiménez – 24 September 2015 – Patients and rats with cirrhosis and ascites have portal hypertension and circulatory dysfunction. Synthetic arginine vasopressin (AVP) receptor agonists able to induce systemic and mesenteric vasoconstriction have shown their usefulness in reducing portal pressure (PP) in this condition.

Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice

Karim Gariani, Keir J. Menzies, Dongryeol Ryu, Casey J. Wegner, Xu Wang, Eduardo R. Ropelle, Norman Moullan, Hongbo Zhang, Alessia Perino, Vera Lemos, Bohkyung Kim, Young‐Ki Park, Alessandra Piersigilli, Tho X. Pham, Yue Yang, Chai Siah Ku, Sung I. Koo, Anna Fomitchova, Carlos Cantó, Kristina Schoonjans, Anthony A.

Subscribe to